RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial.

ABSTRACT:

Background

With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as well as the number of individuals with vascular cognitive impairment/dementia (VCID). No specific FDA-approved treatments for VCID exist. Although clinical evidence supports that angiotensin receptor blockers (ARBs) prevent cognitive decline in older adults, whether ARBs have a similar effect on VCID after stroke is unknown. Moreover, these agents reduce BP, which is undesirable in the acute stroke period, so we believe that giving C21 in this acute phase or delaying ARB administration would enable us to achieve the neurovascular benefits without the risk of unintended and potentially dangerous, acute BP lowering.

Methods

The aim of our study was to determi

SUBMITTER: Ahmed HA 

PROVIDER: S-EPMC6090822 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature